• Explore /
  • Poster
  • / Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.

Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.

Abstract Poster

Authors

null

Arun Rajan

Thoracic and Gastrointestinal Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

Arun Rajan , James L. Gulley , David R. Spigel , Nicholas Iannotti , Jason Claud Chandler , Deborah J.L. Wong , Joseph W. Leach , William Jeffery Edenfield , Ding Wang , Charles H. Redfern , Hans Juergen Grote , Anja von Heydebreck , Mary M. Ruisi , Neru Munshi , Karen Kelly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01772004

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9090)

DOI

10.1200/JCO.2018.36.15_suppl.9090

Abstract #

9090

Poster Bd #

413

Abstract Disclosures

Similar Posters

First Author: Claire F. Verschraegen

First Author: Manish R. Patel

First Author: Andrea B. Apolo

First Author: Mary L. Disis